WT1
WT1 (WT1 transcription factor, also known as Wilms tumour protein, WT-1, WAGR, WIT-2, AWT1, NPHS4 and GUD) is a zinc-finger transcription factor with roles in cellular development and cell survival. It is essential for development of the urogenital system. Browse Assay Genie's current range of WT1 research reagents below, or read on for the biology behind the target.
WT1 is a transcription factor that recognises and binds the DNA sequence 5'-GCG(T/G)GGGCG-3' and regulates the expression of numerous target genes, including EPO. It plays an important role in cellular development and cell survival, and is essential for development of the urogenital system. The source annotation describes both a tumour suppressor role and an oncogenic role for WT1 in tumour formation.
Function appears to depend on the isoform. Isoforms lacking the KTS motif may act as classical transcription factors, whereas isoforms containing the KTS motif may bind mRNA and contribute to mRNA metabolism or splicing. Isoform 1 has lower affinity for DNA and can bind RNA. The WT1 gene encodes a protein with four zinc-finger motifs at the C-terminus and a proline/glutamine-rich domain at the N-terminus. WT1 belongs to the EGR C2H2-type zinc-finger protein family, and HGNC places it in the C2H2-type zinc finger gene group. The protein is found mainly in the nucleus, including the nucleolus, nucleoplasm and nuclear speckles, and is also reported in the cytoplasm.
The gene is named for Wilms tumour, as it is mutated in a small subset of patients with this disease. It shows complex, tissue-specific and polymorphic imprinting, with biallelic expression in some tissues and monoallelic expression from the maternal or paternal allele in others. Multiple transcript variants exist, and some use a non-AUG (CUG) translation initiation codon upstream of the first AUG. There is also evidence that WT1 mRNA undergoes RNA editing in human and rat, in a tissue-restricted and developmentally regulated manner. Mouse and rat both carry a Wt1 ortholog.
WT1 is essential for normal development of the urogenital system, making it a central factor in studies of kidney and genital tract formation.
WT1 is mutated in a subset of Wilms tumour patients and is reported to have both tumour suppressor and oncogenic roles.
WT1 binds a defined GC-rich DNA motif and regulates numerous target genes, including EPO.
KTS-containing WT1 isoforms may bind mRNA and take part in mRNA metabolism or splicing, alongside RNA editing of its own transcript.
WT1 is a transcription factor that binds the DNA sequence 5'-GCG(T/G)GGGCG-3' and regulates numerous target genes, including EPO. It contributes to cellular development and cell survival and is essential for urogenital system development. Some isoforms may also bind mRNA and influence mRNA metabolism or splicing.
WT1 is also called Wilms tumour protein, WT-1, WAGR, WIT-2, AWT1, NPHS4 and GUD, and was previously named Wilms tumour 1. Multiple transcript variants exist. Isoforms with or without the KTS motif differ in function: those lacking it may act as transcription factors, while KTS-containing forms may bind mRNA.
Mouse and rat each have a Wt1 ortholog, and WT1 mRNA editing has been reported in human and rat. The human gene is mutated in a small subset of Wilms tumour patients. Check the datasheet of any product for its validated reactivity.
Related Wilms tumour 1-associated proteins with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P19544; product specifications from Assay Genie datasheets.